U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07897630) titled 'Suprachoroidal Bevacizumab Versus Intravitreal Bevacizumab in Diabetic Macular Edema' on Sept. 15.
Brief Summary: Diabetic macular edema is an eye condition caused by diabetes in which fluid accumulates in the central part of the retina, leading to blurred vision and potentially permanent vision loss. Bevacizumab is a medicine that blocks vascular endothelial growth factor (VEGF), a protein involved in abnormal leakage from blood vessels. It is commonly used as an injection into the eye to treat this condition.
This study aims to compare two methods of delivering bevacizumab in patients with center-involving diabetic macular edema....